Research graph
References from Association between Beta-Lactam concentration and Liver Injury in Critically Ill Patients. Local targets link to admitted publications; unresolved targets remain external evidence.
Pharmacokinetics and pharmacodynamics of beta-lactam antibiotics in critically ill patients
2022 · External reference
Beta-Lactams Toxicity in the Intensive Care Unit: An Underestimated Collateral Damage?
10.3390/microorganisms9071505 · 2021 · External reference
Drug-Induced Liver Injury with Commonly Used Antibiotics in the All of Us Research Program
10.1002/cpt.2930 · 2023 · External reference
Drug-induced liver injury: Pathogenesis, epidemiology, clinical features, and practical management
10.1016/j.ejim.2021.10.035 · 2022 · External reference
Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)
10.1136/flgastro-2021-101886 · 2022 · External reference
ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury
10.1038/ajg.2014.131 · 2014 · External reference
Drug-induced liver injury. Part I: Classification, diagnosis and treatment
10.5114/ceh.2025.148329 · 2025 · External reference
Insufficient beta-lactam concentrations in the early phase of severe sepsis and septic shock
10.1186/cc9091 · 2010 · External reference
Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target
10.1128/aac.05360-11 · 2012 · External reference
An investigation of broad-spectrum antibiotic-induced liver injury based on the FDA Adverse Event Reporting System and retrospective observational study
10.1038/s41598-024-69279-6 · 2024 · External reference
Construction and validation of a meropenem-induced liver injury risk prediction model: a multicenter case-control study
2025 · External reference
EASL Clinical Practice Guidelines: Drug-induced liver injury
10.1016/j.jhep.2019.02.014 · 2019 · External reference
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept
10.1016/j.ijantimicag.2010.06.008 · 2010 · External reference
Immune-mediated drug-induced liver disease
10.1016/s1089-3261(02)00025-9 · 2002 · External reference
Assessment of biliary excretion of piperacillin-tazobactam in humans
10.1128/aac.41.8.1636 · 1997 · External reference
Too much of a good thing: a retrospective study of beta-lactam concentration-toxicity relationships
10.1093/jac/dkx209 · 2017 · External reference
Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential
10.2165/00003495-199447030-00008 · 1994 · External reference
Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper( )
10.1007/s00134-020-06050-1 · 2020 · External reference
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update
10.1093/jac/dki079 · 2005 · External reference
